U.S. PPG Biosensors Market Analysis Report 2024-2030: Rising Adoption of Wearable Devices and Smart Watches - Focus on Heart Rate Monitoring, Blood-Oxygen Saturation, and Blood Pressure
June 26, 2024 10:21 ET
|
Research and Markets
Dublin, June 26, 2024 (GLOBE NEWSWIRE) -- The "U.S. PPG Biosensors Market Size, Share & Trends Analysis Report by Product (Pulse Oximeters, Smart Watches), Application (Heart Rate Monitoring,...
BioStem Technologies Reports Breakthrough Results with AmnioWrap2® in Retrospective Wound Care Study
June 26, 2024 08:30 ET
|
Biostem Technologies
BioStem Technologies Reports Breakthrough Results with AmnioWrap2® in Retrospective Wound Care Study
Agile Therapeutics Inc. Announces Definitive Merger Agreement with Insud Pharma, S.L.
June 26, 2024 07:45 ET
|
Agile Therapeutics, Inc.
Agile Therapeutics will combine with Insud Pharma’s US Subsidiary, Exeltis, expanding an already significant Women’s Health/contraceptive portfolio Agile Therapeutics Common Shareholders expected to...
Pressure BioSciences Partners with Vita-Forte, Largest Global Supplier of Freeze-Dried Acai, to Commercialize Highly Potent, Multi-Antioxidant, UST Nanoemulsion Oral Spray
June 25, 2024 10:23 ET
|
Pressure BioSciences, Inc.
Breakthrough Effectiveness Product Combines Leading Potency Oil-Based Antioxidants (e.g., Acai, Curcumin, Astaxanthin, CoQ10, & More
Industry Leader John Maraganore, Ph.D., Joins Cybrexa Therapeutics as Strategic Advisor
June 25, 2024 08:07 ET
|
Cybrexa Therapeutics
NEW HAVEN, Conn., June 25, 2024 (GLOBE NEWSWIRE) -- Cybrexa Therapeutics, a clinical-stage oncology biotechnology company developing a novel class of tumor-targeting peptide drug conjugate (PDC)...
Allarity Therapeutics’ Dual PARP/Tankyrase Inhibitor, Stenoparib, Continues to Show Extended Clinical Benefit in Advanced Ovarian Cancer
June 25, 2024 08:00 ET
|
Allarity Therapeutics, Inc.
Multiple patients have now exceeded 30 weeks on treatment Boston (June 25, 2024)—Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical...
ExCellThera Announces EMA’s Acceptance under Accelerated Assessment of Market Authorisation Application (MAA) for UM171 Cell Therapy for Patients with Hematological Malignancies who Lack a Readily Available Suitable Donor
June 25, 2024 07:00 ET
|
ExCellThera
Market Authorisation Application (MAA) for ExCellThera's UM171 Cell Therapy accepted under accelerated assessment by the European Medicines Agency
INHALE-3 Study Reveals Positive Readout in Head-to-Head Comparison of Inhaled Insulin vs. Usual Care in T1D; New Data Presented at American Diabetes Association’s 84th Scientific Sessions
June 22, 2024 08:00 ET
|
MannKind
INHALE-3 STUDY REVEALS POSITIVE READOUT IN HEAD-TO-HEAD COMPARISON OF INHALED INSULIN VS. USUAL CARE IN T1D; NEW DATA PRESENTED
Ocugen Announces Data and Safety Monitoring Board Approves Enrollment in High Dose Cohort 3 in GARDian Study for Stargardt Disease
June 21, 2024 07:00 ET
|
Ocugen
• Established Medium Dose as Safe and Tolerable Dose in Current OCU410ST Clinical Trial• DSMB Determination to Proceed with High Dose Cohort Dosing MALVERN, Pa., June 21, 2024 (GLOBE NEWSWIRE) --...
AUROBAC THERAPEUTICS APPOINTS SCIENTIFIC ADVISORY BOARD
June 20, 2024 08:00 ET
|
AUROBAC THERAPEUTICS
The newly formed Scientific Advisory Board chaired by Dr. Marco Taglietti will provide technical and strategic guidance to support AUROBAC’s R&D strategy. Lyon (France), June 20, 2024 ...